Amneal Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Amneal Pharmaceuticals generated cash of $345,577,000, which is more than the previous year. Cash used in financing activities reached the amount of -$212,573,000 last year. Net change in cash is therefore $63,880,000.
Cash Flow
| 2014 | 112.25M | -120.98M | 48.06M |
|---|---|---|---|
| 2015 | 104.88M | -135.62M | -24.98M |
| 2016 | 115.06M | -124.60M | -19.49M |
| 2017 | 234.18M | -98.55M | -95.01M |
| 2018 | 250.23M | -396.37M | 287.67M |
| 2019 | 1.70M | -19.58M | -45.83M |
| 2020 | 379.00M | -317.54M | 131.80M |
| 2021 | 241.82M | -194.18M | -138.12M |
| 2022 | 65.1M | -174.30M | -106.62M |
| 2023 | 345.57M | -69.18M | -212.57M |
AMRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 35.22M | 256.73M | 347.12M | 152.82M | 218.77M | 77.92M | 37.54M | 65.10M | 117.52M | 81.88M |
Operating activities | ||||||||||
Net income | -48.72M | -254.78M | 20.17M | 68.57M | -603.57M | -201.30M | 169.32M | 209.42M | 169.45M | 176.92M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 229.4M | 240.17M | 233.40M | 235.38M | 207.23M | 137.40M | 45.93M | 33.01M | 25.44M | 20.34M |
Stock-based compensation expense | 26.82M | 31.84M | 28.41M | 20.75M | 21.67M | 167.59M | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 26.82M | 31.84M | 28.41M | 20.75M | 21.67M | 167.59M | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 126.28M | -79.71M | -23.62M | 16.78M | -132.72M | 89.08M | 35.25M | -122.48M | -44.65M | -63.66M |
Inventories | -126.18M | -102.39M | -49.01M | -113.78M | -20.39M | -42.87M | -31.82M | -42.58M | -78.07M | -29.62M |
Accounts payable | -94.44M | 109.56M | -43.93M | 307K | -10.25M | -55.21M | 18.10M | 6.26M | 0 | 0 |
Cash generated by operating activities | 345.57M | 65.1M | 241.82M | 379.00M | 1.70M | 250.23M | 234.18M | 115.06M | 104.88M | 112.25M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -43.21M | -90.59M | -52.63M | -66.18M | -97.43M | -97.08M | -114.27M | -124.60M | -117.38M | -79.38M |
Acquisitions Net | 0 | -84.71M | -146.54M | -251.36M | 34.83M | -324.63M | 15.71M | 0 | 0 | 0 |
Cash generated by investing activities | -69.18M | -174.30M | -194.18M | -317.54M | -19.58M | -396.37M | -98.55M | -124.60M | -135.62M | -120.98M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | -182.99M | -375.26M | -200.61M | -258.16M | -243M |
Repurchases of common stock | -2.37M | -3.57M | -2.66M | -863K | -926K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -196.34M | -123.27M | -79.17M | -37.01M | -29.27M | -784.33M | 286.10M | -36.39M | 186.98M | -39.73M |
Cash used in financing activities | -212.57M | -106.62M | -138.12M | 131.80M | -45.83M | 287.67M | -95.01M | -19.49M | -24.98M | 48.06M |
Net Change In Cash | 63.88M | -221.51M | -90.38M | 194.29M | -65.95M | 140.85M | 40.37M | -27.56M | -56.43M | 35.63M |
Cash at end of period | 99.10M | 35.22M | 256.73M | 347.12M | 152.82M | 218.77M | 77.92M | 37.54M | 61.08M | 117.52M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |